A Study to Assess the Safety and Tolerability of E8001 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

August 18, 2023

Study Completion Date

August 18, 2023

Conditions

Healthy Volunteers

Interventions

DRUG

E8001

Intravenous infusion.

DRUG

Placebo

Intravenous infusion.

Trial Locations (1)

Eisai Trial Site #1, Minatoku

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY

NCT04609852 - A Study to Assess the Safety and Tolerability of E8001 in Healthy Male Participants | Biotech Hunter | Biotech Hunter